A liver protein most people have never heard of may explain why some bodies hoard cholesterol no matter how clean the diet looks on paper.
Quick Take
- Researchers found a biological pathway that causes liver cells to destroy their own cholesterol-clearing receptors.
- A protein called cathepsin A, working with a signaling switch called Ral, drives the receptors toward destruction instead of recycling.
- Blocking that protein in mice stabilized the receptors and sharply lowered circulating LDL cholesterol.
- An experimental drug aimed at this pathway already passed a human safety trial, and scientists want to test it for effectiveness next.
How Liver Cells Quietly Sabotage Their Own Cholesterol Defenses
Every liver cell carries LDL receptors, tiny docks that grab bad cholesterol out of the bloodstream and pull it inside for disposal. Scientists at the University of California San Diego found that a steady diet high in cholesterol flips on a signaling system called Ral inside those cells. Once activated, Ral recruits a protein team that pulls LDL receptors off the cell surface and routes them toward the cell’s internal trash system.
That trash system runs on an enzyme called cathepsin A, or CTSA. Instead of letting the receptors get recycled back to the surface to do more work, CTSA tags them for full breakdown. Fewer receptors on the surface means less LDL getting pulled out of the blood, which means cholesterol numbers creep upward even without any single dramatic cause.
Mice Given a CTSA Blocker Saw LDL Cholesterol Fall Sharply
The research team tested whether shutting down this trash-disposal step could reverse the damage. Mice on a high-cholesterol diet received a small-molecule drug designed to block CTSA. Their LDL receptors stopped disappearing, stayed active on the cell surface, and their circulating LDL cholesterol dropped substantially compared to untreated mice.
Blocking Ral itself produced a similar payoff in separate experiments, hitting the pathway earlier in the chain. Both approaches pointed to the same conclusion: interrupt the signal that marks receptors for destruction, and the liver regains its natural ability to clear cholesterol from the blood.
A Shelved Drug Gets a Second Look
What makes this discovery more than a lab curiosity is the existing human data behind it. An investigational drug aimed at this same pathway already went through a Phase I clinical trial, the stage where researchers confirm a drug is safe for people to take, according to the University of California San Diego. The compound had been shelved for other reasons before this cholesterol connection was understood.
Study lead Alan Saltiel said the team hopes to move the drug into a trial testing whether it actually lowers cholesterol in people, not just whether it is safe to take. That next step, a Phase II efficacy trial, has not yet happened. The mouse results are strong, but human proof that this drug lowers cholesterol in patients is still ahead.
Why This Matters for People Who Already Eat Carefully
Heart doctors have long known that cholesterol numbers do not track perfectly with diet. The American Heart Association has said for years that dietary cholesterol raises LDL less consistently than saturated fat, and that people respond to the same meals in very different ways. Genetics, menopause, thyroid problems, and insulin resistance can all push numbers up regardless of what is on the plate.
This new pathway does not replace those explanations, but it adds a plausible mechanical reason why a body under chronic dietary cholesterol exposure can struggle to clear it. It gives doctors and patients a specific process to point to instead of a vague shrug. Current treatment guidelines still lean on lifestyle changes and statins as the backbone of cholesterol management.
For now, the honest summary is this: scientists have identified a real biological switch that helps explain stubborn cholesterol, and they have a drug candidate already cleared as safe in humans. What remains is the trial that proves it actually works for patients, the kind of step that separates a promising finding from an approved treatment on pharmacy shelves.
Sources:
sciencedaily.com, medicalxpress.com, chinagene.cn
